keyword
MENU ▼
Read by QxMD icon Read
search

Second primary, lung cancer

keyword
https://www.readbyqxmd.com/read/29440919/efficacy-and-safety-of-cox-2-inhibitors-for-advanced-non-small-cell-lung-cancer-with-chemotherapy-a-meta-analysis
#1
Ping Dai, Jing Li, Xiao-Ping Ma, Jian Huang, Juan-Juan Meng, Ping Gong
Background: The study of cyclooxygenase-2 (COX-2) inhibitors is now mired in controversy. We performed a meta-analysis to assess the efficacy and safety profile of COX-2 inhibitors in patients with advanced non-small-cell lung cancer (NSCLC). Patients and methods: A literature search of PubMed, EMBASE, the Cochrane Central databases, and ClinicalTrials.gov, up until March 26, 2017, identified relevant randomized controlled trials. Data analysis was performed using Stata 12...
2018: OncoTargets and Therapy
https://www.readbyqxmd.com/read/29409038/second-primary-cancer-in-survivors-of-locally-advanced-non-small-cell-lung-cancer-treated-with-concurrent-chemoradiation-followed-by-surgery
#2
Go Makimoto, Toshio Kubo, Isao Oze, Kadoaki Ohashi, Katsuyuki Hotta, Masahiro Tabata, Junichi Soh, Shinichi Toyooka, Kuniaki Katsui, Nagio Takigawa, Mitsune Tanimoto, Katsuyuki Kiura
The standard treatment for patients with locally advanced non-small-cell lung cancer (LA-NSCLC) is chemoradiotherapy (CRT), but surgical resection following induction CRT can extend overall survival in a select population. However, patients who survive longer are at risk of developing a second primary cancer (SPC). This is the first report to determine the incidence of SPC in survivors with LA-NSCLC after trimodal therapy. Between October 1997 and October 2013, 112 Stage III NSCLC patients underwent trimodal therapy in our hospital...
February 2, 2018: Japanese Journal of Clinical Oncology
https://www.readbyqxmd.com/read/29398155/-interstitial-lung-disease-and-pancreatic-cancer-series-of-two-cases
#3
A Heraudeau, C Ricordel, A Sale, M Lederlin, M Kerjouan, B De Latour, F Llamas-Guttierez, B Desrues, S Jouneau
INTRODUCTION: Pancreatic cancer is often not diagnosed until at a metastatic stage at which point the prognosis is very poor. Pulmonary metastases are pleomorphic, often present at the time of diagnosis and can lead to the discovery of an asymptomatic primary disease. CASE REPORT: We describe two cases aged 60 and 74 years, where imaging identified what was thought to be an interstitial lung disease but which was actually metastasis from pancreatic cancer. In the first case, CT showed multiple excavated pulmonary nodules but the presentation with medullary compression led rapidly to pathological diagnosis on bone lesions...
February 1, 2018: Revue des Maladies Respiratoires
https://www.readbyqxmd.com/read/29391351/t-cell-homing-therapy-for-reducing%C3%A2-regulatory-t-cells%C3%A2-and-preserving-effector-t-cell-function-in-large-solid-tumors
#4
Jiemiao Hu, Chuang Sun, Chantale Bernatchez, Xueqing Xia, Patrick Hwu, Gianpietro Dotti, Shulin Li
PURPOSE: Infused autologous tumor-infiltrating lymphocytes (TILs) and tumor-targeted chimeric antigen receptor (CAR)-T cells typically surround malignant lesions or penetrate small tumor nodules, but fail to penetrate large solid tumors, significantly compromising their antitumor impact. Strategies to overcome this primary challenge are largely required. EXPERIMENTAL DESIGN: We tested the effects of IL-12 plus doxorubicin on T cell penetration and efficacy in solid tumors in a murine lung cancer model, a murine breast carcinoma lung metastasis model and two human xenograft tumor models bearing large tumors (>10 mm)...
February 1, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/29390367/targeted-therapy-with-apatinib-in-a-patient-with-relapsed-small-cell-lung-cancer-a-case-report-and-literature-review
#5
Jun Zhao, Xiaoling Zhang, Chaojie Gong, Jialei Zhang
RATIONALE: Small cell lung cancer (SCLC) is a lethal malignancy. Once relapsed, the disease is irreversible and most of the patients will die of cancer aggravation in 1 to 2 months. In the past several decades, little progress has been made in the systemic treatment of SCLC. Apatinib, as a novel small-molecule tyrosine kinase inhibitor specifically targeting the vascular endothelial growth factor receptor 2 (VEGFR2), has achieved progress in treatment of a variety of cancers. However, there has been no report of the targeted therapy with apatinib in SCLC yet...
December 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29381260/risk-of-second-primary-malignancy-in-patients-with-sinonasal-tumors-a-population-based-cohort-study
#6
Ashwin Ganti, Max A Plitt, Edward C Kuan, Hannah N Kuhar, Pete S Batra, Bobby A Tajudeen
BACKGROUND: The 5-year overall survival rate for patients with sinonasal cancers has remained around 50% for the last 3 decades. Prior studies on head and neck cancers have suggested that 1 reason for poor survival is the frequent development of second primary malignancies (SPMs). The purpose of this study is to assess overall and site-specific risks of SPM following treatment of sinonasal malignancy. METHODS: A retrospective, population-based cohort study was performed on 2614 patients in the Surveillance, Epidemiology, and End Results (SEER) database who were diagnosed with primary sinonasal malignancy between 1973 and 2014...
January 30, 2018: International Forum of Allergy & Rhinology
https://www.readbyqxmd.com/read/29370456/temporal-trends-in-the-risk-of-second-primary-cancers-among-survivors-of-adult-onset-cancers-1980-through-2013-an-australian-population-based-study
#7
Yuanzi Ye, Petr Otahal, Karen E Wills, Amanda L Neil, Alison J Venn
BACKGROUND: The authors' systematic review indicated an increasing trend in the risk of second primary cancers (SPCs) from the 1980s to 2000 when considering studies from the United States and Australia. It is uncertain whether this trend has continued to increase since 2000. METHODS: The current study was a population-based study of 51,802 individuals with adult-onset cancers identified in the Tasmanian Cancer Registry. Patients with a first cancer diagnosis made between 1980 and 2009 were followed up to December 2013...
January 25, 2018: Cancer
https://www.readbyqxmd.com/read/29332372/measurement-and-modeling-of-indoor-radon-concentrations-in-residential-buildings
#8
Ji Hyun Park, Sungim Whang, Hyun Young Lee, Cheol-Min Lee, Dae Ryong Kang
Objectives: Radon, the primary constituent of natural radiation, is the second leading environmental cause of lung cancer after smoking. To confirm a relationship between indoor radon exposure and lung cancer, estimating cumulative levels of exposure to indoor radon for an individual or population is necessary. This study sought to develop a model for estimate indoor radon concentrations in Korea. Especially, our model and method may have wider application to other residences, not to specific site, and can be used in situations where actual measurements for input variables are lacking...
January 8, 2018: Environmental Health and Toxicology
https://www.readbyqxmd.com/read/29317551/characteristics-of-real-world-metastatic-non-small-cell-lung-cancer-patients-treated-with-nivolumab-and-pembrolizumab-during-the-year-following-approval
#9
Sean Khozin, Amy P Abernethy, Nathan C Nussbaum, Jizu Zhi, Melissa D Curtis, Melisa Tucker, Shannon E Lee, David E Light, Anala Gossai, Rachael A Sorg, Aracelis Z Torres, Payal Patel, Gideon Michael Blumenthal, Richard Pazdur
BACKGROUND: Evidence from cancer clinical trials can be difficult to generalize to real-world patient populations, but can be complemented by real-world evidence to optimize personalization of care. Further, real-world usage patterns of programmed cell death protein 1 (PD-1) inhibitors following approval can inform future studies of subpopulations underrepresented in clinical trials. MATERIALS AND METHODS: We performed a multicenter analysis using electronic health record data collected during routine care of patients treated in community cancer care clinics in the Flatiron Health network...
January 9, 2018: Oncologist
https://www.readbyqxmd.com/read/29310384/different-histological-types-of-triple-metachronous-primary-lung-carcinomas-in-1-patient-case-report
#10
Jee Hyuk Kim, Seung Yong Park, Seoung Ju Park, Myoung Ja Chung, Heung Bum Lee
INTRODUCTION: The documented incidence of multiple primary lung cancer has increased as a result of the widespread use of early detection tools. We report the successful surgical treatment of a case who had consecutive metachronous adenocarcinoma and squamous cell carcinoma of the lung after successful treatment for small cell carcinoma of the lung.A 73-year-old man underwent a routine health check-up. Computed tomography showed ground-glass opacity in the upper lobe of the right lung, which was diagnosed as small cell carcinoma...
December 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29304946/do-surrogate-endpoints-better-correlate-with-overall-survival-in-studies-that-did-not-allow-for-crossover-or-reported-balanced-postprogression-treatments-an-application-in-advanced-non-small-cell-lung-cancer
#11
Mahmoud Hashim, Boris M Pfeiffer, Robert Bartsch, Maarten Postma, Bart Heeg
BACKGROUND: In previous studies, correlation between overall survival (OS) and surrogate endpoints like objective response rate (ORR) or progression-free survival (PFS) in advanced non-small cell lung cancer (NSCLC) was poor. This can be biased by crossover and postprogression treatments. OBJECTIVES: To evaluate the relationship between these two surrogate endpoints and OS in advanced NSCLC studies that did not allow for crossover or reported balanced post-progression treatments...
January 2018: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/29290257/primary-resistance-to-osimertinib-due-to-sclc-transformation-issue-of-t790m-determination-on-liquid-re-biopsy
#12
R Minari, P Bordi, M Del Re, F Facchinetti, F Mazzoni, F Barbieri, A Camerini, C E Comin, L Gnetti, C Azzoni, R Nizzoli, B Bortesi, E Rofi, P Petreni, N Campanini, G Rossi, R Danesi, M Tiseo
OBJECTIVES: EGFR T790M mutation is the most common mechanism of resistance to first-/second-generation EGFR tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer (NSCLC) and could be overcome by third-generation EGFR-TKIs, such as osimertinib. Liquid biopsy, a non-invasive technique used to test the presence of the resistant mutation, may help avoiding tissue re-biopsy. However, analysing only circulating-free DNA, information about other less frequent and coexisting resistance mechanisms may remain unrevealed...
January 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/29290249/a-phase-i-trial-of-afatinib-and-bevacizumab-in-chemo-na%C3%A3-ve-patients-with-advanced-non-small-cell-lung-cancer-harboring-egfr-mutations-okayama-lung-cancer-study-group-trial-1404
#13
Takashi Ninomiya, Naoyuki Nogami, Toshiyuki Kozuki, Daijiro Harada, Toshio Kubo, Kadoaki Ohashi, Shoichi Kuyama, Kenichiro Kudo, Akihiro Bessho, Nobuaki Fukamatsu, Nobukazu Fujimoto, Keisuke Aoe, Takuo Shibayama, Keisuke Sugimoto, Nagio Takigawa, Katsuyuki Hotta, Katsuyuki Kiura
OBJECTIVE: In advanced epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC), treatment with afatinib, a second-generation EGFR-tyrosine kinase inhibitor (TKI), confers a significant survival benefit over platinum-based chemotherapy. The first-generation EGFR-TKIs gefitinib and erlotinib in combination with bevacizumab have improved progression-free survival. We hypothesized that the combination of afatinib with bevacizumab would further improve efficacy, and conducted a phase I trial to test this hypothesis...
January 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/29277187/-synchronous-multiple-primary-lung-cancer-dignosed-%C3%A2-by-different-phenotype-genotype-a-case-report-and-literature-review
#14
Xin Li, Zhirong Zhang, Yili Fu, Jinbai Miao, Bin Hu
In recent years, based on low-dose computed tomography (CT) scan developed for physical examination, the number of synchronous multiple primary lung cancer (SMPLC) has gradually increased. The research showed the morbidity of SMPLC up to 0.2%-8%. The current diagnostic criteria of SMPLC is Martini-Melamed criteria. SMPLC: (1) Tumours should be located distantly and separately; (2) Histological types: Different histology; If same histology, they should be located at different segment, lobe or lung and originated from carcinoma insitu...
December 20, 2017: Zhongguo Fei Ai za Zhi, Chinese Journal of Lung Cancer
https://www.readbyqxmd.com/read/29248665/a-case-of-a-primary-lung-cancer-comprised-of-adenocarcinoma-and-atypical-carcinoid-tumor-with-both-components-harboring-braf-p-v600e-mutation
#15
Andrea M Olofson, Laura J Tafe
Mixed morphology lung tumors are rare; this is the second report of a combined NSCLC and atypical carcinoid tumor. Next generation sequencing was performed on both histologically distinct patterns which identified that both components harbored a BRAF p.V600E mutation. Molecular studies inform our knowledge of the biology and aid in treatment decisions for mixed morphology lung cancers.
December 14, 2017: Experimental and Molecular Pathology
https://www.readbyqxmd.com/read/29245323/lung-adenocarcinoma-and-pulmonary-metastases-coexist-in-a-patient-with-papillary-thyroid-carcinoma-a-case-report
#16
Changhai Cheng, Jinxin Zhou, Xiaonan Shao
RATIONALE: Multiple primary malignant tumors (MPMTs) are defined as 2 or more independent primary malignancies of different histologies/origins in the same individual. Although the incidence of MPMTs is being increasing, second primary cancer (SPC) is still rare and difficult to distinguish from metastasis. Here, we present a case of thyroid carcinoma with lung metastasis and primary lung cancer. PATIENTS CONCERNS: The patient was a 66-year-old man diagnosed of papillary thyroid carcinoma (PTC) with lymph nodes, lung, and skeletons metastases...
December 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29234921/a-phase-ii-trial-of-ifosfamide-combination-with-recommended-supportive-therapy-for-recurrent-sclc-in-second-line-and-heavily-treated-setting
#17
Ichidai Tanaka, Kenji Kawada, Masahiro Morise, Tetsunari Hase, Hiroaki Hayashi, Akihiko Sokai, Asuki Fukatsu, Masashi Kondo, Fumio Nomura, Yoshinori Hasegawa
PURPOSE: The response rate of ifosfamide (IFM) monotherapy for small-cell lung cancer (SCLC) is reported as 42.4% in Japanese package insert. However, these efficacy data are based on clinical studies conducted in 1970s. This phase II study evaluated the efficacy and safety of IFM combination with recommended current supportive therapy for recurrent SCLC in second-line and heavily treated setting. METHODS: Recurrent SCLC patients pretreated with one to three prior regimens received IFM monotherapy (1...
December 12, 2017: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/29228636/the-efficacy-of-40-mg-versus-dose-de-escalation-to-less-than-40-mg-of-afatinib-giotrif-as-the-first-line-therapy-for-patients-with-primary-lung-adenocarcinoma-harboring-favorable-epidermal-growth-factor-mutations
#18
Chien-Ying Liu, Chih-Liang Wang, Shih-Hong Li, Ping-Chih Hsu, Chih-Hung Chen, Ting-Yu Lin, Chih-Hsi Kuo, Yueh-Fu Fang, How-Wen Ko, Chih-Teng Yu, Tai-Yun Yang, Cheng-Ta Yang
The choice of a first-line therapy for lung cancer is a crucial decision that can impact the survival as well as the quality of life of a patient. Inhibitors of epidermal growth factor receptor (EGFR) such as afatinib, erlotinib, and gefitinib have previously been used to treat non-small cell lung cancer harboring favorable EGFR mutations. Although afatinib has greater efficacy than other EGFR inhibitors, adverse events related to its use can result in the discontinuation of the therapy. In this study, we compared the therapeutic efficacy in lung cancer patients of a regimen of 40 mg/day of afatinib with that of a lower dose regimen of <40 mg/day resulting either from a lower starting dose of 30 mg/day or dose adjustment...
November 14, 2017: Oncotarget
https://www.readbyqxmd.com/read/29212524/successful-management-of-retinal-metastasis-from-renal-cancer-with-everolimus-in-a-monophthalmic-patient-a-case-report
#19
Ismail Essadi, Issam Lalya, Mohamed Kriet, Abdelhamid El Omrani, Rhizlane Belbaraka, Mouna Khouchani
BACKGROUND: The retina is an uncommon site for metastases, in particular from solid tumors. Some authors have reported a recent increase in the incidence of metastases in infrequent sites, such as brain or bone, probably due to the expanded treatment options and the resulting improved survival. Choroidal metastasis is the most common type of intraocular malignancy. The most common primary sites associated with choroidal metastasis are breast cancer in women and lung cancer in men. Treatment options are limited, but they must be discussed and adapted to the patient profile...
December 7, 2017: Journal of Medical Case Reports
https://www.readbyqxmd.com/read/29197312/development-of-multiple-primary-cancers-in-lung-cancer-patients-appalachian-versus-non-appalachian-populations-of-kentucky
#20
Vira Pravosud, Bin Huang, Thomas Tucker, Nathan L Vanderford
OBJECTIVES: The aim of this study was to investigate whether patients with lung cancer in Appalachian Kentucky are more likely to develop multiple primary cancers than patients in non-Appalachian Kentucky. Additional analyses were conducted to identify other factors that may be associated with an increased hazard of developing multiple primary cancers in patients with lung cancer. METHODS: The data for this retrospective, population-based cohort study of 26,456 primary lung cancer patients were drawn from the Kentucky Cancer Registry...
December 2017: Southern Medical Journal
keyword
keyword
89877
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"